Unlike existing approved PCSK9 inhibitors, Klug said lerodalcibep does not need refrigeration, is a smaller injectable (based on volume or amount), and patients can administer their own injections.

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?